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Abstract
Rift Valley fever (RVF) is an arboviral zoonosis that primarily affects ruminants but can also
cause illness in humans. The increasing impact of RVF in Africa and Middle East and the
risk of expansion to other areas such as Europe, where competent mosquitos are already
established, require the implementation of efficient surveillance programs in animal popula-
tions. For that, it is pivotal to regularly assess the performance of existing diagnostic tests
and to evaluate the capacity of veterinary labs of endemic and non-endemic countries to
detect the infection in an accurate and timely manner. In this context, the animal virology
network of the MediLabSecure project organized between October 2016 and March 2017
an external quality assessment (EQA) to evaluate the RVF diagnostic capacities of benefi-
ciary veterinary labs. This EQA was conceived as the last step of a training curriculum that
included 2 diagnostic workshops that were organized by INIA-CISA (Spain) in 2015 and
2016. Seventeen veterinary diagnostic labs from 17 countries in the Mediterranean and
Black Sea regions participated in this EQA. The exercise consisted of two panels of samples
for molecular and serological detection of the virus. The laboratories were also provided
with positive controls and all the kits and reagents necessary to perform the recommended
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F, Adzic B, Al Ameer M, Djadjovski I, et al. (2020)
External quality assessment of Rift Valley fever
diagnosis in 17 veterinary laboratories of the
Mediterranean and Black Sea regions. PLoS ONE
15(9): e0239478. https://doi.org/10.1371/journal.
pone.0239478
Editor: Tetsuro Ikegami, University of Texas
Medical Branch at Galveston, UNITED STATES
Received: August 3, 2020
Accepted: September 7, 2020
Published: September 28, 2020
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diagnostic techniques. All the labs were able to apply the different protocols and to provide
the results on time. The performance was good in the molecular panel with 70.6% of partici-
pants reporting 100% correct results, and excellent in the serological panel with 100% cor-
rect results reported by 94.1% of the labs. This EQA provided a good overview of the RVFV
diagnostic capacities of the involved labs and demonstrated that most of them were able to
correctly identify the virus genome and antibodies in different animal samples.
Introduction
Rift Valley fever (RVF) is a zoonotic viral disease that primarily affects animals (mainly rumi-
nants and camels), but also humans. The causative agent of RVF is an arbovirus belonging to
the Phlebovirus genus in the Phenuiviridae family that was first identified in the Rift Valley of
Kenya in 1930 [1]. It is transmitted to animals by mosquitos of the genus Aedes and Culex [2].
Although humans can also be infected by mosquito bites, the main route of transmission is the
contact with body fluids and tissues of infected animals or the consumption of contaminated
animal products such as raw or unpasteurised milk [3].
The clinical manifestations of the disease in animals vary depending on age and the species
affected. Young animals are significantly more likely to succumb than adults. Sheep and goats
are highly susceptible while adult cattle and camels are usually asymptomatic. In most cases
the animals exhibit fever, lethargy, hepatic and splenic lesions, bloody diarrhoea and abortions.
Severe disease can occur suddenly causing death without previous symptoms [2, 4].
In humans the disease is usually less severe, and the most common form is a self-limiting,
flu-like illness. However, 2–5% of infected individuals may develop severe forms of the disease
with haemorrhagic fever, encephalitis, retinitis, renal failure and miscarriage [5, 6]. Overall
fatality rates that were historically low (around 2%) have dramatically increased (up to 40%) in
the most recent outbreaks [7–9].
RVF is widespread in Africa, with spill-over to the Comoros Archipelago (including
Mayotte), Madagascar, Saudi Arabia and Yemen [10]. Until now, active circulation has not
been detected in Europe but RVFV introduction is a real concern due to the presence of com-
petent vectors [11].
RVF occurs in periodic epidemics that are associated with climatic, hydrologic and socio-
economic factors. Rainfall variability is the key parameter controlling the dynamics of mos-
quito vectors and thereby influencing the transmission of the virus [12]. Outbreaks typically
occur after unusual heavy rainfalls that provide a perfect environment for infected mosquito
eggs to hatch in flooded areas [7].
The disease can have an enormous impact on the health of people and livestock and on the
socio-economic outcomes. For example, in Egypt in 1976, 200.000 human cases and 600
deaths were reported [13]. In Sudan the disease caused in 2007 and 2008 747 human cases
with 230 deaths [14]. The outbreaks in Somalia and Kenya in 2006–2007 were estimated to
have cost 471 and 66 million US Dollars, respectively, due to livestock death, closure of live-
stock markets and reduced sales of animal products [15, 16]. Yemen and Saudi Arabia also suf-
fered dire economic losses (5 and 107 million dollars, respectively) during the outbreaks in
2000–2001 [16].
RVF outbreaks always represent a great challenge for human and animal diagnostic labora-
tories, healthcare systems and public health institutions, as has been recently recognized in the
first outbreak in Niger [8].
PLOS ONE External quality assessment of Rift Valley fever diagnosis in 17 veterinary laboratories
PLOS ONE | https://doi.org/10.1371/journal.pone.0239478 September 28, 2020 2 / 14
Human epidemics are often preceded by epizootics in livestock. Hence, surveillance of RVF
in animals can act as an early warning system to prevent spill-over to humans [2, 3]. Moreover,
RVF is a notifiable disease to the World Organization of Animal Health (OIE) due to the sani-
tary and economic consequences derived from its emergence in a free country. Although there
are some commercial vaccines available (inactivated and live attenuated) for livestock in
endemic countries, no vaccine for human use has yet been authorized, and the development of
more reliable and safe vaccines remains a One Health challenge [17, 18]. Therefore, the imple-
mentation of surveillance systems in animals and mosquitos and the development of the diag-
nostic capacities of the veterinary laboratories is essential in the fight against the disease.
Diagnostic methods for RVFV detection include virus isolation, reverse-transcription polymer-
ase chain reaction (RT-PCR) and serological tests. Isolation procedures are time-consuming and
require high biocontainment facilities (BSL-3). By contrast, molecular methods, such as RT-PCR
can be easily applied in basic laboratories, are fast and sensitive, allowing timely detection of the
pathogen and early outbreak response. Among the serological diagnostic tools, ELISA tests are the
most widely used with several kits commercially available. Virus neutralization is the OIE pre-
scribed test for international livestock trade but it requires the use of live virus and is not recom-
mended for use in laboratories outside endemic areas without appropriate biosecurity facilities.
MediLabSecure is an EU-funded project whose main objective is to create a framework for
collaboration to promote arbovirus surveillance under a One Health approach (animal,
human and entomological) in 19 countries of the Mediterranean and Black Sea regions [19–
21]. The beneficiary countries recognized RVF as a common health priority, due to the devas-
tating effects it can have in human and animal health and its potential to emerge beyond its
usual geographic range. As part of the capacity building activities promoted by MediLabSe-
cure, in 2015 and 2016 specific workshops were organized at INIA-CISA (Madrid, Spain) to
improve the RVFV diagnostic capacities of the veterinary laboratories of the network. After
these training sessions, an external quality assessment (EQA) was organized between October
2016 and March 2017 to evaluate the capacity of the participating labs to incorporate the
acquired molecular and serological diagnostic techniques, and to promote their implementa-
tion for routine use in surveillance programs.
This study reports the results of the inter-laboratory trial and provides relevant information
about the current RVFV diagnostic capacities of veterinary labs in the Mediterranean and
Black Sea regions. Besides, this exercise enabled an extensive reproducibility assessment of the
recommended tests for RVFV diagnostics.
Materials and methods
Call for participation
An invitation letter was sent by the coordinating team of the MediLabSecure animal virology
network (INIA-CISA, Madrid, Spain) in May 2016 to all the involved veterinary laboratories
(n = 18). Seventeen laboratories accepted to participate (94.4%). The participation was free of
charge and entailed the publication of comparative results in an anonymous manner.
Preparation of EQA panel
Samples for virus genome detection. For the molecular diagnosis of RVFV, each partici-
pant received a blind coded panel of 10 samples (8 positive and 2 negative), as shown in Table 1.
Two viral strains were used for the preparation of the panel: Namibia 2010 [22] and the
MP12 vaccine strain (ZH548-MP12-G2-P1) [23]. Both viral stocks were inactivated using ß-
propiolactone. Absence of residual infectivity was confirmed after three consecutive passages
in Vero cells.
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Several dilutions of inactivated virus stock were spiked in different matrices (serum, blood,
liver or spleen homogenates) from healthy non-infected sheep to mimic positive field samples.
Liver and spleen homogenates from healthy sheep were included as negative samples. Nucleic
acid extraction was performed from 200 μl of sample using the QIAamp1 Cador Pathogen
Mini Kit (QIAGEN), following the manufacturer’s protocol. In the final step, RNA was eluted
in 50 μl of nuclease-free water. All samples were tested in duplicates by real-time RT-PCR
(RRT-PCR) for RVFV detection using primers and probe described by Drosten et al. [24, 25].
Briefly, the RRT-PCR mix was prepared in a final volume of 25 μl per sample containing 5 μl
of RNA template, 1 μM of each primer (RVS and RVAs), 0.2 μM of probe (RVP), RT-PCR
enzyme mix and RT-PCR buffer of the commercial AgPath-ID one-step RT-PCR kit (Life
Technologies, Thermo Fisher Scientific). All reactions were carried out in a Mx3005P equip-
ment with the following thermal profile: reverse transcription at 45˚C for 10 min, initial PCR
activation step at 95˚C for 10 min, followed by 45 cycles of 15 sec at 95˚C, 20 sec at 56˚C, and
30 sec at 72˚C. According to the obtained Ct values, a collection of 10 samples was finally
selected (Table 1). The samples were aliquoted (1 ml) and each vial was lyophilized and stored
at 4˚C until delivery to the participant laboratories. Prior to delivery, the lyophilized panel was
resuspended in DNAse free water and was fully analysed to verify the integrity of the samples.
Triplicates of each lyophilised sample were analysed by RRT-PCR at INIA-CISA by 3 techni-
cians. The reference Ct value was established as the mean of the nine repetitions (Table 1). The
within-laboratory repeatability of the assay was evaluated for the positive samples, obtaining a
coefficient of variation (CV) range of 0.89–3.19% (mean 1.99%).
Two positive controls were delivered with the panel: (1) a positive nucleic acid extraction
control consisting of cell culture medium spiked with inactivated RVFV MP12 vaccine strain
to obtain, after a 1/10 dilution, an expected Ct value of 32±2 (this sample was lyophilized and
stored at 4˚C until delivery) and (2) a positive reaction control consisting of RVFV positive
RNA with an expected Ct value of 32±2 (this sample was stored at -80˚C until delivery).
Samples for antibody detection. For the serological diagnosis of RVFV, each participant
received a blind coded panel of 10 sheep sera (6 positive and 4 negative). The positive samples
consisted of sera from 3 sheep vaccinated with the formalin-inactivated RVFV vaccine from
Onderstepoort Biological Products (OBP, Onderstepoort, South Africa). The sera were inacti-
vated by heating at 56˚C for 2 hours and then analysed by ELISA (ID Screen Rift Valley Fever
Competition Multi-species, IDVET) and virus neutralization test using the MP12 vaccine
strain (ZH548-MP12-G2-P1). According to the obtained results, several dilutions were
selected to prepare the positive samples of the panel (Table 2). The negative samples consisted
of sera from healthy cattle. Each sample was aliquoted (130 μl) and stored at -20˚C until ship-
ment. The reference quantitative OD values of the panel were established at INIA-CISA by
repeating the assay 3 times by three different technicians. The within-laboratory repeatability,
estimated as CV of the OD values obtained, ranged over 3.87–23.66% (mean 14.68%).
EQA details
This exercise was conceived as a follow-up of the diagnostic training workshops that the bene-
ficiary labs attended at INIA-CISA in 2015 and 2016. The main objective was to evaluate the
capacity of the labs to perform the diagnosis of RVFV using the protocols, kits and reagents
that were used during the training sessions.
For the molecular detection of RVFV we selected the OIE recommended RRT-PCR proto-
col [25] using the primers and probe described by Drosten et al. [24] targeting the RVFV-M
segment.
PLOS ONE External quality assessment of Rift Valley fever diagnosis in 17 veterinary laboratories



































































































































































































































































































































































































































































































































































































































































































































PLOS ONE External quality assessment of Rift Valley fever diagnosis in 17 veterinary laboratories
PLOS ONE | https://doi.org/10.1371/journal.pone.0239478 September 28, 2020 6 / 14
For serological diagnosis of the infection, we recommended the use of the ID Screen Rift
Valley Fever Competition Multi-species (IDVet) ELISA, a commercially available kit that has
been widely used in surveillance programs, with optimal sensitivity and specificity [26, 27].
Detailed standard operating procedures were distributed and all the reagents and kits were
provided to each laboratory including the nucleic acid extraction kit (QIAamp1 Cador Path-
ogen Mini Kit, QIAGEN), the RT-PCR kit (AgPath-ID one-step RT-PCR kit, Life Technolo-
gies, Thermo Fisher Scientific), primers and probe [24] and the mentioned IDVet ELISA kit.
As explained before, extraction and reaction positive controls were also delivered to all the
labs.
For the molecular panel, specific instructions for the reconstitution of the lyophilized sam-
ples as well as for preparation of the positive extraction control were provided to all the labs.
For the serological panel, the participant laboratories were asked to analyse the panel samples
using the provided commercial kit following manufacturer’s instructions.
Additionally, it was suggested to analyse both panels using alternative methods (other pro-
tocols that may be established in the labs) and report the results together with those derived
from the recommended methods.
The lyophilized samples, the positive extraction control and the nucleic acid extraction and
ELISA kits were shipped at room temperature. The panel of sera, the RT-PCR kit, the positive
reaction control and the primers and probe were shipped in dry ice.
A number code was assigned to each laboratory to ensure a blind analysis of the results.
Ethics statement
The tissue samples and sera used for the preparation of the EQA panels were selected from the
biobanks of INIA-CISA (Madrid, Spain) and IZSAM (Teramo, Italy). None of them were
Fig 1. Participant laboratories.
https://doi.org/10.1371/journal.pone.0239478.g001
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specifically collected for this study. Positive sheep sera were obtained from a vaccination study
that was conducted by IZSLER in accordance with Italian law for animal protection and with
the European Directive 2010/63/EU. The experiment was approved by the Internal Animal
Welfare body and authorized by the local authorities (n. 998 22/09/2015 Italian Minister of
Health). The organs and blood used to prepare the rest of the panel samples were obtained
from the biobank of INIA-CISA. All of them originated from animal studies that were autho-
rized by INIA Animal Experimentation Ethics Committee according to European Directive
2010/63/EU (Spanish Royal Decree 53/2013).
Results
Seventeen laboratories submitted results, representing 17 countries from the Mediterranean
and Black Sea regions (Fig 1).
Fig 2. RVFV genome detection EQA performance of individual laboratories. Bars above the baseline indicate correct results; bars below the baseline indicate
incorrect results.
https://doi.org/10.1371/journal.pone.0239478.g002
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Virus genome detection
A total of 18 datasets were received from the 17 labs, including one double set from laboratory
#1 that used an alternative method apart from the recommended one. The results of all the
labs using the recommended method are shown in Table 1 and Fig 2.
The labs reported the use of seven different thermocyclers: Rotor-Gene 3000 (6 labs),
Applied Biosystems 7500 (4 labs), Applied Biosystems 7300 (2 labs), StepOnePlus (2 labs), Aria
Mx Agilent (1 lab), Bioer Gene Max (1 lab) and Stratagene Mx3005 (1 lab).
Twelve out of 17 laboratories (70.6%) reported 100% of correct results using the recom-
mended protocols and reagents. The laboratory providing two different RT-PCR datasets pro-
duced 100% of correct results with the recommended protocol and 3 false negative results (R6,
R7 and R8) with the commercial kit RVFV dtec-RT-qPCR Test, GPS Genetic PCR Solutions.
In general, the reported Ct values were in line with the reference values. However, three
labs (#5, #8 and #13) reported Ct values slightly higher (2–4 Cts) than expected in some sam-
ples and 2 labs (#6 and #15) reported Ct values slightly lower (2–4 Cts) than expected. It is
noteworthy that in one lab (#12) the reported Ct values were considerably lower (6–9 Cts)
than the reference values.
Only one lab (#17) reported more than two incorrect results. In fact, this lab misidentified
70% of the samples and the reported Ct values were higher than expected.
The percentage of laboratories with correct results increased as the expected Ct value of the
sample decreased (higher viral load), as shown in Table 1. Samples R5 and R8 with the lowest
Ct values were correctly assigned by all the labs.
The reproducibility of the assay in terms of qualitative results was excellent (kappa = 1) for
the twelve laboratories with 100% of correct results, substantial for 2 laboratories that failed in
1 sample (#6 and #7, kappa values of 0.62 and 0.73, respectively) and moderate for 1 laboratory
that failed in 2 samples (#16, kappa = 0.55) (Table 1).
The reproducibility of the assay for the positive samples, in terms of quantitative values (Ct)
obtained, expressed as CV, ranged from 11.97 to 16.20% (mean: 13.47%; Table 1).
Antibody detection
A total of 18 datasets were received from the 17 labs, including one double set from laboratory
#1 that used an alternative ELISA kit apart from the recommended one. The results of all the
labs with the recommended method are shown in Table 2.
Sixteen out of 17 labs (94.1%) reported correct results for all the samples using the recom-
mended ELISA method showing an excellent reproducibility between laboratories (kappa
value = 1). Only one laboratory (#3) obtained one incorrect result (sample R9 was reported as
doubtful instead of positive), reaching also a high reproducibility (kappa value = 0.82). The
laboratory providing two different datasets produced 100% of correct results with the recom-
mended kit and four false negative results (R1, R4, R9 and R10) with the alternative kit (Inge-
zim FVR Compac, Ingenasa).
Discussion
Since the beginning of the MediLabSecure project in 2014, the animal virology network has
implemented numerous actions to strengthen awareness, diagnosis and control of emerging
vector-borne viruses of great impact in human and animal health. As part of the capacity
building activities, two workshops were organized in 2015 and 2016 to provide specialized
training in molecular and serological diagnosis of the arboviruses that were identified as major
health concerns in the region, namely West Nile virus and RVFV.
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A further step of this training curriculum was the organization in 2016–2017 of two exter-
nal quality assessments to evaluate the acquired capacities of each laboratory to detect both
viruses from animal samples. In this article we present the results of the RVFV inter-laboratory
assay.
Despite the increasing incidence of RVFV in Africa with recent and severe outbreaks in
new countries such as Niger [8] and continuous spill-over to other regions as Saudi Arabia
and Comoro Islands [28], very few external quality assessments have been implemented to
evaluate the capacity of the labs to accurately detect RVFV genome and antibodies in clinical
samples and to harmonize the diagnostic techniques. In the human virology sector, one EQA
was organized by the ENIVD network in 2012 to evaluate the molecular diagnostic capacities
of 30 labs of 16 countries [29]. In the veterinary sector, only one EQA was organized in 2013–
2014 by IZSAM in collaboration with WHO and FAO in the framework of the REMESA proj-
ect [27]. Ten laboratories in six countries from Europe and North Africa participated to assess
their molecular and serological diagnostic performances.
The EQA we present here has a number of particular features that differentiate it from pre-
vious RVFV EQAs. In the first place, the number and geographical coverage of the involved
laboratories. In this case, 17 veterinary laboratories from 17 non-EU countries have partici-
pated including North Africa, Balkans, Black Sea and Middle East regions. Of these countries
only 3 labs in Morocco, Tunisia and Algeria had participated in the previous EQA organized
by IZSAM [27]. Secondly, this EQA was designed as the last step of a 3-years training curricu-
lum to evaluate the capacity of the trainees to incorporate the techniques acquired during the
workshops into their own laboratories. Last, but not least, the labs were provided with all the
reagents and kits required to perform the diagnostic assays following the standard operating
procedures that were distributed during the workshops. The objective was to avoid difficulties
of the labs to purchase/obtain the requested diagnostic materials and facilitate as much as pos-
sible the participation of all beneficiary institutions. Moreover, and as part of the preparedness
actions promoted by MediLabSecure, positive nucleic acid extraction and reaction controls
were also provided to be used as quality controls during this EQA but also to serve as reference
material for future diagnostic activities of the labs. Such material is otherwise difficult to
obtain.
The combination of molecular and serological methods in the same EQA is also an added
value, as the surveillance of RVFV in animals requires this complementary approach, particu-
larly in non-endemic countries.
The panel for RVFV genome detection consisted of 10 samples containing various concen-
trations of two RVFV strains. Apart from the well characterized strain Namibia 2010 that was
used in the previously mentioned EQA by Monaco and colleagues [27], we included an addi-
tional strain, the MP12 vaccine strain, that has been used as live attenuated vaccine in animals
and has been proposed as vaccine candidate for humans [18, 23].
In previous EQAs, the viruses were diluted in human plasma [29] or bovine serum [27], but
in this case, and to mimic as much as possible the clinical samples that the vet labs would
receive during surveillance and outbreak investigations, the two viruses were spiked in differ-
ent target organs/matrices (serum, blood, liver and spleen).
The panel for antibody detection consisted of six sera from vaccinated sheep with different
antibody titres and four sera from healthy cattle. Altogether, we consider that both panels rep-
resent a comprehensive proficiency test to efficiently evaluate the actual RVFV diagnostic
capacities of the labs.
The performance in the molecular panel was good in general terms, as 70.6% of participants
reported 100% correct results. Surprisingly, one laboratory reported very poor results, with
one false positive and six false negative results. It seems that a technical error could occur
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during the extraction process obtaining a significantly lower RNA yield in the whole panel. In
fact, and as part of the corrective measures implemented after the analysis of EQA results, a
new panel of samples was shipped to this laboratory obtaining 100% concordant results. So, if
we discard the results of this laboratory, the percentage of labs with 100% correct results would
increase to 75%. Only one lab reported a false positive result and three labs reported one, two
and two false negative results, respectively.
Overall, the reported Ct values were concordant with the reference values, although some
variability (ranging from 1 to 4 Ct units) was observed in certain laboratories, which could be
due to the different thermocyclers used and/or to minor performance variations in the entire
analysis process. Only one laboratory (#12) reported very discrepant Ct values in the whole
panel, with a deviation of 6–9 Ct units lower than the reference data. Considering that all the
labs used exactly the same protocols, reagents and kits, the only lab-specific element was the
thermocycler, and although differences in calibration or in threshold setting could contribute
to certain Ct variation, it can hardly account for such a big difference in RT-PCR performance
as compared with the rest of participants. Moreover, another lab used the same equipment
(Applied Biosystems 7300) and obtained Ct values concordant with the reference data.
Only one laboratory (#1) reported the results of an additional RRT-PCR method using a
commercial kit (RVFV dtec-RT-qPCR Test) purchased from “GPS Genetic PCR Solutions”
company. In this case, three positive samples (two with expected Ct>32 and one with expected
Ct<25) were wrongly assigned as negative. Since only one lab used this commercial kit, the
apparent low sensitivity of this method should be cautiously interpreted.
It is worth noting that the equipment and expertise necessary to apply RRT-PCR techniques
was available in all the labs, which confirms that the use of RRT-PCR has substantially
increased and is nowadays the primary molecular diagnostic method in the involved veteri-
nary labs.
The results of the antibody detection EQA were excellent, with 100% of correct results in all
labs except for one positive sample that lab #3 reported as doubtful. Competition values (not
shown) obtained in all the labs were concordant with the reference values. The analysis of the
panel with an additional ELISA kit (Ingezim FVR Compac Ingenasa), used by laboratory #1,
yielded 40% of incorrect results (false negatives). However, this data should be interpreted
with precaution as only one laboratory used the kit.
The unique characteristics of this EQA, in which all the protocols and technical compo-
nents (except the thermocycler and ELISA reader) are the same in all participant labs allows to
accurately evaluate the reproducibility of the selected diagnostic methods. In this way, we
could verify that the RRT-PCR protocol designed by Drosten et al. [24] is a reliable method for
accurate detection of RVFV genome. The use of this protocol in previous EQAs in human and
animal samples also yielded very good results [27, 29] and it has also been successfully used to
identify the presence of the viral genome in clinical samples during epidemiological investiga-
tions [10].
In the case of the antibody detection exercise, our results confirm optimal performance of
the IDVet kit, with high reproducibility values, as all the labs reported 100% concordant results
(except one positive serum identified as doubtful). This commercial kit is widely used for
RVFV diagnosis in ruminants as demonstrated in the EQA conducted by IZSAM, where all
the labs selected this kit for the analysis of the sera [27]. Furthermore, this ELISA displayed the
best analytical sensitivity and specificity values in a ring trial organized to evaluate the perfor-
mance of different ELISAs for the diagnosis of RVFV infections [26].
In conclusion, this exercise provides a good overview of the RVFV diagnostic capacities of
veterinary labs in 17 EU-neighbouring countries. Most of the participant labs demonstrated
their ability to correctly identify RVFV genome and antibodies in different animal samples. All
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the labs were able to apply the recommended diagnostic protocols and to provide the results
on time. Notably, before the implementation of this MediLabSecure diagnostic training pro-
gram in 2015, only 37.5% of the beneficiary labs had established protocols to diagnose RVFV
infections. The proposed training strategy with two workshops (molecular and serological
diagnosis) followed by this EQA has proved very useful in upgrading the capacities of the labs.
However, regular refresher trainings and EQA programs should be encouraged to maintain
and improve this expertise.
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Ángel Jiménez-Clavero, Jovita Fernández-Pinero.
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Writing – original draft: Elisa Pérez-Ramı́rez.
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Federica Monaco, Alejandro Brun, Miguel Ángel Jiménez-Clavero, Jovita Fernández-
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24. Drosten C, Göttig S, Schilling S, Panning M, Schmitz H, Asper M, et al. Rapid detection and quantifica-
tion of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift
Valley fever virus, Dengue virus and Yellow fever virus by real-time reverse transcription-PCR. J Clin
Microbiol. 2002; 40: 2323–2330. https://doi.org/10.1128/jcm.40.7.2323-2330.2002 PMID: 12089242
25. World Organisation for Animal Health (OIE). Rift Valley fever. Chapter 3.1.18. Manual of diagnostic
tests and vaccines for terrestrial animals. 2018.
26. Kortekaas J, Kant J, Vloet R, Cêtre-Sossah C, Marianneau P, Lacote S, et al. European ring trial to eval-
uate ELISAs for the diagnosis of infection with Rift Valley fever virus. J Virol Methods. 2013; 187: 177–
181. https://doi.org/10.1016/j.jviromet.2012.09.016 PMID: 23022325
27. Monaco F, Cosseddu GM, Doumbia B, Madani H, El Mellouli F, Jiménez-Clavero MA, et al. First Exter-
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